Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States

References

Page 1

	Year	Citations
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Silvia de Sanjosé, Wim Quint, Laia Alemany, The Lancet Oncology Invasive Cervical CancerEpidemiologyCervical Cancer ScreeningPrecancerous LesionsCervical Cancer	2010	2.7K
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014 Sarah Reagan-Steiner, David Yankey, Jenny Jeyarajah, MMWR Morbidity and Mortality Weekly Report Adolescents Aged 13–17Hpv Vaccination CoverageImmunodeficienciesVaccine HesitancyPreventive Medicine	2015	834
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler, The Lancet Oncology VaccinationCervical Cancer ScreeningHpv-16/18 As04-adjuvanted VaccineCervical CancerCervical Health	2011	693
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years Darron R. Brown, Susanne K. Kjær, Kristján Sigurðsson, The Journal of Infectious Diseases	2009	627
Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. Shannon Stokley, Jenny Jeyarajah, David Yankey, PubMed Hpv InfectionVaccine HesitancyUnited StatesCervical Cancer PreventionPreventive Medicine	2014	537
Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010 Lauri E. Markowitz, Susan Hariri, Carol Y. Lin, The Journal of Infectious Diseases	2013	520
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial BMJ	2010	413
Pneumococcal Disease after Pneumococcal Vaccination Claire V. Broome, Richard R. Facklam, David W. Fraser New England Journal of Medicine	1980	344
Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease Beatriz Serrano, Laia Alemany, Sara Tous, Infectious Agents and Cancer	2012	294
Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study Dorota M. Gertig, Julia Brotherton, Alison C Budd, BMC Medicine	2013	268

Page 1